Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.

3.

Abiraterone: moving up in line?

Strijbos M PhD.

ESMO Open. 2018 Jan 12;3(1):e000318. doi: 10.1136/esmoopen-2017-000318. eCollection 2018. No abstract available.

4.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
5.

Reply to the letter to the editor 'Can we trust burnout research?' by Bianchi et al.

Banerjee S, Preusser M, Tabernero J, Strijbos M.

Ann Oncol. 2017 Oct 1;28(10):2625-2626. doi: 10.1093/annonc/mdx329. No abstract available.

PMID:
28961831
6.

New treatment options for metastatic renal cell carcinoma.

Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH.

ESMO Open. 2017 May 9;2(2):e000185. doi: 10.1136/esmoopen-2017-000185. eCollection 2017. Review.

7.

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH.

Ann Oncol. 2017 Jul 1;28(7):1590-1596. doi: 10.1093/annonc/mdx196.

8.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

9.

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.

Rodriguez-Vida A, Strijbos M, Hutson T.

ESMO Open. 2016 May 25;1(3):e000013. eCollection 2016. Review.

10.

How trained volunteers can improve the quality of hospital care for older patients. A qualitative evaluation within the Hospital Elder Life Program (HELP).

Steunenberg B, van der Mast R, Strijbos MJ, Inouye SK, Schuurmans MJ.

Geriatr Nurs. 2016 Nov - Dec;37(6):458-463. doi: 10.1016/j.gerinurse.2016.06.014. Epub 2016 Jul 26.

PMID:
27471215
11.

Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.

Beuselinck B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, Joniau S, Oyen R, De Wever L, Strijbos M, Paridaens R, Schöffski P.

Clin Genitourin Cancer. 2014 Oct;12(5):e205-14. doi: 10.1016/j.clgc.2014.04.004. Epub 2014 May 9.

PMID:
24861951
12.

Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.

Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P.

BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15.

13.
14.

A new approach for rapid and reliable enumeration of circulating endothelial cells in patients.

Kraan J, Strijbos MH, Sieuwerts AM, Foekens JA, den Bakker MA, Verhoef C, Sleijfer S, Gratama JW.

J Thromb Haemost. 2012 May;10(5):931-9. doi: 10.1111/j.1538-7836.2012.04681.x.

15.

Circulating tumour cells and circulating endothelial cells as biomarkers in oncology.

Strijbos MH.

Acta Clin Belg. 2011 Sep-Oct;66(5):332-6. Review.

PMID:
22145267
16.

External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study.

Kraan J, Sleijfer S, Strijbos MH, Ignatiadis M, Peeters D, Pierga JY, Farace F, Riethdorf S, Fehm T, Zorzino L, Tibbe AG, Maestro M, Gisbert-Criado R, Denton G, de Bono JS, Dive C, Foekens JA, Gratama JW.

Cytometry B Clin Cytom. 2011 Mar;80(2):112-8. doi: 10.1002/cyto.b.20573. Epub 2010 Nov 10.

17.

mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells.

Strijbos MH, van Krimpen BA, Debets R, Kraan J, Sleijfer S, Gratama JW, Lamers CH.

Thromb Haemost. 2010 Aug;104(2):318-26. doi: 10.1160/TH09-08-0594. Epub 2010 Jun 29.

PMID:
20589320
18.

Levels of circulating endothelial cells in normotensive and severe preeclamptic pregnancies.

Strijbos MH, Snijder CA, Kraan J, Lamers CH, Gratama JW, Duvekot JJ.

Cytometry B Clin Cytom. 2010 Nov;78(6):382-6. doi: 10.1002/cyto.b.20537.

19.

Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.

Strijbos MH, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, Miller MC, de Wit R, Terstappen LW, Sleijfer S.

Eur J Cancer. 2010 Jul;46(11):2027-35. doi: 10.1016/j.ejca.2010.03.030.

PMID:
20399640
20.

On the origin of (CD105+) circulating endothelial cells.

Strijbos MH, Verhoef C, Gratama JW, Sleijfer S.

Thromb Haemost. 2009 Aug;102(2):347-51. doi: 10.1160/TH08-11-0762.

PMID:
19652886
21.

Quantification of circulating endothelial cells by flow cytometry.

Strijbos MH, Kraan J, Lamers CH, Sleijfer S, Gratama JW.

Clin Cancer Res. 2009 May 15;15(10):3640; author reply 3640-1. doi: 10.1158/1078-0432.CCR-09-0160. No abstract available.

22.

Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia?

Strijbos MH, Landburg PP, Nur E, Teerlink T, Leebeek FW, Rijneveld AW, Biemond BJ, Sleijfer S, Gratama JW, Duits AJ, Schnog JJ; CURAMA study group.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):63-7. doi: 10.1016/j.bcmd.2009.02.007. Epub 2009 Apr 7.

PMID:
19356955
23.

Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage.

Strijbos MH, Rao C, Schmitz PI, Kraan J, Lamers CH, Sleijfer S, Terstappen LW, Gratama JW.

Thromb Haemost. 2008 Oct;100(4):642-7.

PMID:
18841287
24.

Circulating endothelial cells in oncology: pitfalls and promises.

Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, Sleijfer S.

Br J Cancer. 2008 Jun 3;98(11):1731-5. doi: 10.1038/sj.bjc.6604383. Epub 2008 May 27. Review.

25.

Potential biomarkers in metastatic gastrointestinal stromal tumors.

Strijbos MH, Kraan J, Sleijfer S, Gratama JW.

Clin Cancer Res. 2007 Oct 15;13(20):6244. No abstract available.

26.

Cells meeting our immunophenotypic criteria of endothelial cells are large platelets.

Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, Gratama JW.

Cytometry B Clin Cytom. 2007 Mar;72(2):86-93.

27.

[A positive approach to the obstructive sleep apnea syndrome].

Strijbos MH, Vos PJ, Folgering HT, Manni JJ.

Ned Tijdschr Geneeskd. 1990 Nov 3;134(44):2121-3. Dutch. No abstract available.

PMID:
2247166
28.

[Continuous positive pressure administration via a nose mask in obstructive sleep apnea syndrome].

Folgering H, Strijbos M, Manni JJ.

Ned Tijdschr Geneeskd. 1989 Jul 1;133(26):1332. Dutch. No abstract available.

PMID:
2674735
29.

Supraglottic laryngectomy: short- and long-term functional results.

Strijbos M, van den Broek P, Manni JJ, Huygen PL.

Clin Otolaryngol Allied Sci. 1987 Aug;12(4):265-70.

PMID:
3665136
30.

[Supraglottic laryngectomy; oncologic and functional results].

van den Broek P, Strijbos M, Manni JJ, Huygen PL.

Ned Tijdschr Geneeskd. 1986 Sep 6;130(36):1608-11. Dutch. No abstract available.

PMID:
3762765

Supplemental Content

Loading ...
Support Center